An international, multi-center, open-label, 2-arm phase III trial of adjuvant bevacizumab in triple-negative breast cancer
An international, multi-center, open-label, 2-arm phase III trial of adjuvant bevacizumab in triple-negative breast cancer
David Cameron, MD (Professor of Oncology at Edinburgh University)